Xcout Intel
MATRICELF
Matricelf Ltd, a biotechnology company, develops a platform for autologous tissue engineering for various medical conditions. The company’s regenerative medicine platform intends to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson’s disease, and myocardial infarction, as well as for 3D bioprinting. The company has a strategic collaboration with Sheba Medical Center for the development and clinical advancement of its neural tissue implant product for the treatment of spinal cord injury. The company has a strategic collaboration with CiRA Foundation for the development of regenerative manufacturing technologies and the evaluation of iPSC-based neural tissue engineering for therapeutic applications. The company was incorporated in 2019 and is based in Ness Ziona, Israel.
Subscribe to see MATRICELF’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
MATRICELF at a glance
MATRICELF is a biotech company headquartered in Ness Ziona, Israel, founded in 2019. It is publicly listed (MTLF) with a market capitalisation of $24.3M. Xcout tracks 13 named people at MATRICELF, including Gil Hakim (CEO).
MATRICELF leadership
- Gil HakimCEO
- Sigal RussoCFO
- Tamar Harel Adar, PhDCTO
- Alon Sinai, PhDCo-Founder, Deputy CEO President
- Prof. Tal Dvir, PhDCo-Founder CSO
- Tal Ben NeriahVP Operations
7 more named people on record for MATRICELF, with roles, board committees and tenure — see the full roster →
MATRICELF competitors
A few of MATRICELF's closest competitors — see the full list of competitors and alternatives →
CellCure Neurosciences is an Israeli biotechnology company developing cell-based therapies derived from pluripotent stem cells, notably retinal pigment epithelium cells for treating retinal diseases such as geographic atrophy associated with dry age-related macular degeneration. Its intended customers and beneficiaries include ophthalmology researchers, clinical partners, and patients with degenerative retinal conditions.
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Cellect Biotechnology Ltd. was an Israeli biotechnology company developing cell-selection and regenerative-medicine technologies, including its ApoGraft platform for enriching stem cells from bone marrow or other cell sources. Its products were intended primarily for clinical and research applications involving hematopoietic stem-cell transplantation and cell-based therapies.
CoreTissue BioEngineering Inc. is a biotechnology company headquartered in Yokohama, Japan, operating out of the Life Science Research Center. The company specializes in research, development, and regenerative medicine applications within the life sciences sector. It provides advanced biomedical engineering solutions from its Japanese laboratory headquarters.
Get MATRICELF's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on MATRICELF in Xcout Intel
- 13 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access